Cytokinetics Leverages Athlete Partnership to Broaden HCM Awareness

Event summary

  • Cytokinetics launched 'On Track with HCM,' a campaign featuring Olympic gold medalist Sydney McLaughlin-Levrone and her father, Willie McLaughlin, who received a heart transplant after battling HCM.
  • The campaign includes a website and eight videos designed to support HCM patients and caregivers, addressing both clinical and non-clinical aspects of the disease.
  • HCM affects approximately 1 in 350 people in the U.S., with a significant portion remaining undiagnosed.
  • Cytokinetics' MYQORZO™ (aficamten) is approved for symptomatic obstructive HCM and is under investigation for non-obstructive forms.

The big picture

Cytokinetics' partnership with a high-profile athlete represents a shift towards patient-centric marketing within the biopharmaceutical industry, recognizing the importance of addressing the emotional and lifestyle challenges associated with chronic diseases. HCM, a relatively common but often underdiagnosed condition, presents a significant unmet need, and Cytokinetics is positioning itself to capture a larger share of this market with both its existing and pipeline therapies. The campaign’s focus on the ‘whole person’ reflects a broader trend towards holistic healthcare solutions.

What we're watching

Brand Perception
The success of the campaign hinges on McLaughlin-Levrone's ability to resonate with patients and caregivers, potentially impacting Cytokinetics’ brand image and driving adoption of its HCM therapies.
Regulatory Landscape
The ongoing investigation of aficamten for non-obstructive HCM will be crucial, as broader label expansion could significantly increase the patient population eligible for treatment.
Market Penetration
The pace at which physicians and patients incorporate MYQORZO into treatment protocols will dictate the drug’s commercial success, especially given the competition in the cardiovascular space.